Please update your Flash Player to view content.

Bio Pro Classes:

Tuesday, 10 Mar 2015
Category: Bio Pro Classes

Thursday, 12 Mar 2015
Category: Bio Pro Classes

Tuesday, 17 Mar 2015 - Wednesday, 18 Mar 2015
Category: Bio Pro Classes

Tuesday, 24 Mar 2015 - Tuesday, 07 Apr 2015
Category: Bio Pro Classes

Wednesday, 25 Mar 2015
Category: Bio Pro Classes

Thursday, 26 Mar 2015
Category: Bio Pro Classes

Thursday, 26 Mar 2015
Category: Bio Pro Classes

Wednesday, 01 Apr 2015
Category: Bio Pro Classes

Monday, 06 Apr 2015 - Monday, 27 Jul 2015
Category: Bio Pro Classes

Monday, 06 Apr 2015 - Monday, 08 Jun 2015
Category: Bio Pro Classes

Event Registration Cart

Your cart is empty.

 Meeting with Representative Vega Pederson -

 discussing women in STEM in Oregon.


In late November, Oregon Bio board members Jennifer Stoll (Allergan), Jennifer Fox, Ph.D., (OTRADI /OBI) and Dianne Danowski Smith (Publix Northwest) meet with state Representative Jessica Vega Pederson (D-Dist. 47) to discuss opportunities for women in STEM careers in Oregon. A success agenda is being planned!


News Flash

  • Portland bioscience incubator's expansion almost complete

    The finishing touches are underway on the expansion of Southwest Portland's Bioscience Incubator.

    The current 13,000-square-foot space is growing by another 3,800 square feet downstairs in the same building, at 4640 S.W. Macadam Ave.

    The incubator, managed by the Oregon Translational Research and Development Institute, currently houses six companies. Within six weeks of its opening in 2013, it filled up, so demand is definitely there for laboratory and office space in Portland.

    "I'm proud we got enough interest that we could expand within a year and a half," said Jennifer Fox, executive director of OTRADI and the incubator. "The space is allowing us to almost double the number of companies. It's a great vote of confidence."

    The expansion will accommodate up to four new startups and provide space for two current tenants. One of those, Floragenex, will move into the newly built-out space. Another, AbSci, will take over the additional lab space vacated by Floagenex.

    Floragenex, a spinoff of the University of Oregon, specializes in DNA sequencing. AbSci is developing technology that enables scientists to produce antibotides and proteins used in cancer and hormone therapies. New companies joining the incubator are TomegaVax, an OHSU spinoff developing an HIV treatment vaccine, and GeTein, an in-vitro diagnostic company.

    Fox said she'd eventually like to add office space to house health IT startups. The incubator recently expanded to Corvallis. Fox would like to open an outpost in Bend as well.

    Elizabeth Hayes
    Staff Reporter-
    Portland Business Journal

Bioscience News

  • With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at 5,008.10, marking the third day in history with a close above 5,000. Since 95% of US publicly traded biotech companies are listed on the Nasdaq exchange, the team at BIO couldn’t help but join the excitement. Back in 2000, the Nasdaq index was flourishing with dot coms. At that point there was no Facebook or Netflix and Google wasn’t public. Read More >

  • Each week in February, GMO Answers highlighted a different commodity crop, its role in agricultural production and its relationship to biotechnology and GMOs. Weeks 1, 2 and 3 looked at corn, soybean and cotton.  Week 4 explored a few commodity crops that are non-GM, including cassava, peanuts and rice, and the potential for GM varieties of these crops. Cassava Cassava is the third largest source of food carbohydrates in the tropics after rice and maize, provides basic sustenance for over half a billion people…According to a study Read More >

  • A recent survey conducted by BIO confirms the increasing reliance on R&D outsourcing as biotech and pharmaceutical companies indicate speed, flexibility, and access to specialized resources drive pipeline strategies/decisions.  Despite these biopharma companies having veteran teams with outsourcing experience, our survey results help quantify inefficiencies facing nearly every relevant organization. The survey polled a group of small biotech companies about their experience with CROs and other contract service providers.  Over 80% of the companies surveyed were actively outsourcing portions of their pre-clinical or clinical pipelines.  Nearly two-thirds of the companies surveyed dedicated more than 20% of their entire budget to these services in 2014.  In addition, every company surveyed plans on maintaining Read More >

Underwriting Sponsors

Sustaining Sponsors

Principal Sponsors

Home | Bio in Oregon | BioPro Training | Events | Sponsors | Member Resources | News | About Us

Oregon Bioscience Association Copyright © 2014. All Rights Reserved.